Moderation of thyroid hormones for the relationship between amyloid and tau pathology
Jeong Hyeon Byeon,Min Soo Byun,Dahyun Yi,Joon Hyung Jung,Bo Kyung Sohn,Yoon Young Chang,Nayeong Kong,Gijung Jung,Hyejin Ahn,Jun-Young Lee,Yun-Sang Lee,Yu Kyeong Kim,Dong Young Lee,KBASE Research Group,Chul-Ho Sohn,Inhee Mook- Jung,Murim Choi,Yu Jin Lee,Seokyung Hahn,Hyun Jung Kim,Mun Young Chang,Seung Hoon Lee,Na Young Han,Jisoo Pae,Hansoo Park,Jee Wook Kim,Jong-Min Lee,Dong Woo Lee,Seok Woo Moon,Hyewon Baek,Yoon-Keun Kim,Jong-Won Kim,Seung-Ho Ryu,Shin Gyeom Kim,Jong Inn Woo,Sang Eun Kim,Gi Jeong Cheon,Koung Mi Kang,Jee-Eun Park,Hyeong Gon Yu,Hyo Jung Choi,Young Min Choe,Kwangsoo Kim,So Yeon Jeon,Woo Jin Kim,Kang Ko,Jun Ho Lee,Sung Wook Park,Haejung Joung,Han Na Lee,Gihwan Byeon,Kiyoung Sung,Dong Kyun Han,Seung Min Han,Min Jung Kim,Min Jae Kim,Seo Hee Park,Mimi Kim,Woojin Cha,Hyeryeon Yeom,Musung Keum,Min Jeong Kim,Donghee Kim,Kyungtae Kim,Jeongmin Choi,Hye Ji Choi,Bae Han Sol,Dohyun Woo,Seunghyuk Ha
DOI: https://doi.org/10.1186/s13195-024-01534-4
2024-07-23
Abstract:Background: Altered thyroid hormone levels have been associated with increased risk of Alzheimer's disease (AD) dementia and related cognitive decline. However, the neuropathological substrates underlying the link between thyroid hormones and AD dementia are not yet fully understood. We first investigated the association between serum thyroid hormone levels and in vivo AD pathologies including both beta-amyloid (Aβ) and tau deposition measured by positron emission tomography (PET). Given the well-known relationship between Aβ and tau pathology in AD, we additionally examined the moderating effects of thyroid hormone levels on the association between Aβ and tau deposition. Methods: This cross-sectional study was conducted as part of the Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease (KBASE) cohort. This study included a total of 291 cognitively normal adults aged 55 to 90. All participants received comprehensive clinical assessments, measurements for serum total triiodothyronine (T3), free triiodothyronine (fT3), free thyroxine (fT4), and thyroid-stimulating hormone (TSH), and brain imaging evaluations including [11C]-Pittsburgh compound B (PiB)- PET and [18F] AV-1451 PET. Results: No associations were found between either thyroid hormones or TSH and Aβ and tau deposition on PET. However, fT4 (p = 0.002) and fT3 (p = 0.001) exhibited significant interactions with Aβ on tau deposition: The sensitivity analyses conducted after the removal of an outlier showed that the interaction effect between fT4 and Aβ deposition was not significant, whereas the interaction between fT3 and Aβ deposition remained significant. However, further subgroup analyses demonstrated a more pronounced positive relationship between Aβ and tau in both the higher fT4 and fT3 groups compared to the lower group, irrespective of outlier removal. Meanwhile, neither T3 nor TSH had any interaction with Aβ on tau deposition. Conclusion: Our findings suggest that serum thyroid hormones may moderate the relationship between cerebral Aβ and tau pathology. Higher levels of serum thyroid hormones could potentially accelerate the Aβ-dependent tau deposition in the brain. Further replication studies in independent samples are needed to verify the current results.